In 2004, using the cDNA microarray results as a golden standard, Hans et al found that the expression of CD10, BCL-6 and MUM1 can be combined to divide cases of DLBCL into GCB and non-GCB subgroups with an outcome closely related to prognosis.

• 2004年Hans等人运用cDNA微阵列作为参照，采用三种基因蛋白产物(CD10，BCL-6，MUM1)免疫组化标记方法，据免疫表型将DLBCL简单地分成预后有显著差异的GCB与non-GCB两类分子亚型，同样提示前者预后较好。